At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
BGB-DXP604 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating BGB-DXP604, BGB-DXP593, and 1 other intervention for Healthy. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The primary objective of this study is to investigate the safety and tolerability of BGB-DXP604 alone and in combination with BGB-DXP593 in healthy participants
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedDec 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedDec 16, 2020
Enrollment StartDec 9, 2020
Primary CompletionMay 21, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.5 years ago
Interventions
BGB-DXP604drug
Administered as intravenous (IV) infusion over 30 to 60 minutes
BGB-DXP593drug
Administered as intravenous (IV) infusion over 30 to 60 minutes
Placebodrug
Placebo to match BGB-DXP593
Placebodrug
Placebo to match BGB-DXP604